BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25374001)

  • 41. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
    Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
    J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
    Ozretic P; Alvir I; Sarcevic B; Vujaskovic Z; Rendic-Miocevic Z; Roguljic A; Beketic-Oreskovic L
    Int J Biol Markers; 2018 Jan; 33(1):109-115. PubMed ID: 28777433
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
    Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
    Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
    Lim ST; Park CH; Kim SY; Nam SJ; Kang EY; Moon BI; Lee HJ; Jeon YW; Gwak H; Suh YJ
    PLoS One; 2018; 13(5):e0197523. PubMed ID: 29768496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients).
    Eltohamy MI; Badawy OM; El kinaai N; Loay I; Nassar HR; Allam RM; Sakr MA
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3581-3589. PubMed ID: 30583686
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
    Zhao Y; Schaafsma E; Cheng C
    Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M
    Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers.
    Lindner AU; Lucantoni F; Varešlija D; Resler A; Murphy BM; Gallagher WM; Hill ADK; Young LS; Prehn JHM
    J Mol Med (Berl); 2018 Oct; 96(10):1025-1037. PubMed ID: 30069746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer.
    Ginter PS; McIntire PJ; Cui X; Irshaid L; Liu Y; Chen Z; Shin SJ
    Clin Breast Cancer; 2017 Nov; 17(7):544-549. PubMed ID: 28410844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Characteristics and prognostic analysis of Triple-negative Breast Cancer: Single institute experience.
    Maka VV; Pancha H; Shukla SN; Talati SS; Shah PM; Patel KM; Anand AS; Shah SA; Patel AA; Parikh S
    Gulf J Oncolog; 2016 Jan; 1(20):38-44. PubMed ID: 27050178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential roles of Bcl2L12 and its short variant in breast cancer lymph node metastasis.
    Chien ST; Yang TF; Yang MC; Hsu CM; Hong YR; Lee TM
    Oncol Rep; 2015 Aug; 34(2):961-71. PubMed ID: 26082034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
    Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer.
    Ayadi EZ; Cherif B; Ben Hamed Y; Mokni M; Rebai A; Ayadi H; Jlidi R
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3557-3564. PubMed ID: 30583683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
    Jiang T; Shi W; Wali VB; Pongor LS; Li C; Lau R; Győrffy B; Lifton RP; Symmans WF; Pusztai L; Hatzis C
    PLoS Med; 2016 Dec; 13(12):e1002193. PubMed ID: 27959926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.